Scientists peel away the mystery of JAK enzymes, which play roles in everything from eczema to ulcerative colitis
Pharmaceutical ads are difficult to avoid in American television programming and a growing number of them promote a class of ...
Ocean Biomedical advances in cancer immunotherapy
PROVIDENCE, RI - Ocean Biomedical (NASDAQ: OCEA) has announced research findings that show its immunotherapy candidates can work synergistically with tyrosine kinase inhibitors (TKIs), potentially ...
Nature7d
The anaplastic lymphoma kinase in the pathogenesis of cancer
Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase first identified ... (ALCL), driving transformation through many molecular mechanisms. In this Review, we will analyse how ...
Contract Pharma1h
Hoth Therapeutics, OnTargetx R&D Partner to Advance Research for Cancer Therapeutic
Hoth Therapeutics Inc., a biopharmaceutical company committed to developing innovative therapies for unmet medical needs, has collaborated with OnTargetx R&D Inc. to accelerate research for its cancer ...
Medscape7d
Targeted Drugs in Oncology: New Names, New Mechanisms, New Paradigm
The molecular mechanisms of action ... extracellular portion of RTKs and small-molecule inhibitors of their tyrosine kinase activity are strategies in more advanced phases of clinical development.
ophthalmologytimes14d
Tyrosine kinase inhibitor: An alternative treatment for non–small-cell lung cancer metastasis to the choroid
Investigators conducted a retrospective review that spanned 10 years with the goals of describing the clinical ...
Nature23y
New mechanisms in heptahelical receptor signaling to mitogen activated protein kinase cascades
Together, these novel mechanisms of GPCR-mediated MAPK regulation ... including phospholipase Cγ and the non-receptor tyrosine kinase c-Src. EGFR activation also leads to tyrosine phosphorylation ...
Ocean Biomedical Announces Breakthrough Findings in EGFR-Mutant Lung Cancer and Plans for FDA Alignment on Next-Stage Development
Company Poised to Enter Booming Bispecific Antibody Market Amid Growing Pharma Interest Providence, RI, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Ocean Biomedical (NASDAQ: OCEA) today announced newly ...
Too Old to Operate7d
Bruton’s tyrosine kinase inhibition re-sensitizes multidrug-resistant DLBCL tumors driven by BCL10 gain-of-function mutants to venetoclax.
Disparate pathogenic mechanisms complicate precision-medicine efforts to treat diffuse large B-cell lymphoma (DLBCL), the most common lymphoma diagnosis. Though potentially curable with frontline ...